Civil Plaintiff
Biogen Agrees to Settle Drug Kickback Allegations For $900 Million
Biogen Inc on Wednesday said it had cinched a $900 million deal to resolve a whistleblower lawsuit accusing the biotech company of paying doctors kickbacks to prescribe multiple sclerosis drugs just days before a trial was scheduled to kick off.
The agreement-in-principle, which Biogen disclosed in a quarterly earning report, came ahead of a trial set to begin next Tuesday in federal court in Boston in a lawsuit brought by a former employee.
The settlement is subject to the approval of the U.S. Justice Department, which did not intervene in the case as it could have under the False Claims Act but instead left it to the ex-employee Michael Bawduniak to litigate on his own.
